Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318082 · ClinicalTrials.gov registry record · Phase 1
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
A Phase 1 study of Chronic Versus Graft Host Disease, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02318082 is a Phase 1 study of Chronic Versus Graft Host Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02318082, a Phase 1 study of Chronic Versus Graft Host Disease, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is a way of gaining new knowledge about the treatment for cGVHD that has not responded to steroids. This research study is evaluating a drug called Interleukin-2 (IL-2) as a possible treatment for cGVHD. In this Phase I study, the investigators are looking to see if 8- week individual patient dose- escalated IL-2 therapy for cGVHD is safe and its effects on your immune cells.
Conditions Studied
Interventions
- DRUG Interleukin-2
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Insitute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-02 |
| Est. Completion | 2020-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318082
The ClinicalTrials.gov registry entry for NCT02318082 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Versus Graft Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Interleukin-2 is the first listed.
NCT02318082 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02318082 about?
NCT02318082 is a clinical study titled "Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD". This research study is a way of gaining new knowledge about the treatment for cGVHD that has not responded to steroids. This research study is evaluating a drug called Interleukin-2 (IL-2) as a possible treatment for cGVHD. In this Phase I study, the investigators are looking to see if 8- week indiv...
What is the current status of trial NCT02318082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-02. Estimated completion is 2020-04-22.
What conditions does trial NCT02318082 study?
This clinical trial studies the following conditions: Chronic Versus Graft Host Disease.
What interventions are being tested in trial NCT02318082?
The interventions under investigation include: Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT02318082?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02318082 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.